Drug intelligence / Profile preview

khk6188

Development stage: Phase 2
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Oral

Overview

KHK6188 is a small molecule drug developed by Kyowa Kirin. It acts as an agonist of the cannabinoid receptor 2 (CB2), which is involved in modulating inflammatory responses and nociceptive (pain) transmission. The primary indication for KHK6188 has been neuropathic pain, specifically postherpetic neuralgia—a chronic pain condition following shingles. Clinical trials have evaluated its efficacy and safety in this context, with oral administration being the studied route[1][2][3][4].

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on khk6188.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on khk6188.

Explore the full profile